Theriva Biologics, Inc.
TOVXHealthcare|Biotechnology|US
$0.17
-0.00 (-1.13%)
DCF Value
$1.08
Cash / Share
$0.25
Clinical Trials (15)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04692181 SYN-004 Safety and Tolerability in Allo-HCT Subjects | Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics | P1P2 | Active | 36 | RCT, Double-blind | SYN-004, Ribaxamase or Placebo |
| NCT07701486 A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer | Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV | P1P2 | Recruiting | 6 | Open-label | VCN-01 oncolytic adenovirus (zabilugene almadenorepvec), Nab-paclitaxel + Gemcitabine |
| NCT02495623 A Study of the Effect of SYN-010 on Subjects With IBS-C | Irritable Bowel Syndrome With Constipation (IBS-C) | P2 | Completed | 63 | RCT, Double-blind | SYN-010 21 mg, SYN-010 42 mg, Placebo |
| NCT02563106 A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI | Clostridium Difficile, Clostridium Infections | P2 | Completed | 413 | RCT, Double-blind | SYN-004, Placebo |
| NCT03763175 Efficacy and Safety of SYN-010 in IBS-C | Irritable Bowel Syndrome With Constipation | P2 | Terminated | 59 | RCT, Double-blind | SYN-010 21 mg, SYN-010 42 mg, Placebo |
| NCT02419001 A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy | Healthy Volunteers | P1P2 | Completed | 11 | RCT, Open-label | Period 1 - Treatment Sequence AB, Period 1 - Treatment Sequence AC, Period 2 - Treatment Sequence AB, Period 2 - Treatment Sequence AC |
| NCT02493036 A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C | Irritable Bowel Syndrome With Constipation (IBS-C) | P2 | Completed | 54 | Open-label | SYN-010 |
| NCT02473640 A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy | Healthy Volunteers With Ileostomy | P1P2 | Completed | 15 | Open-label | SYN-004, Esomeprazole, Ceftriaxone |
| NCT05673811 Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer | Pancreatic Adenocarcinoma, Metastatic | P2 | Completed | 112 | RCT, Open-label | Nab-paclitaxel, Gemcitabine |
| NCT04815993 Pharmacokinetics, Safety, and Tolerability of SYN-020 | Enteritis Caused by Radiation (Disorder) | P1 | Completed | 24 | Open-label | SYN-020 delayed release capsule |
| NCT05045833 Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020 | Enteritis Caused by Radiation | P1 | Completed | 40 | RCT, Double-blind | SYN-020 Delayed Release Capsule |
| NCT02045589 A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | P1 | Completed | 8 | Open-label | Gemcitabine, Abraxane® |
| NCT02045602 Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors | Locally Advanced Solid Tumors, Metastatic Solid Tumors | P1 | Completed | 42 | Open-label | Gemcitabine, Abraxane® |
| NCT05057715 huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | Pancreatic Cancer, Serous Ovarian Cancer | P1 | Terminated | 13 | Open-label | VCN-01, huCART-meso Cells |
| NCT03799744 Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma | Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck | P1 | Unknown | 20 | Open-label | Durvalumab |